首页 | 本学科首页   官方微博 | 高级检索  
     


Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration
Authors:Julia A. Elvin  Laurie M. Gay  Rita Ort  Joseph Shuluk  Jennifer Long  Lauren Shelley  Ronald Lee  Zachary R. Chalmers  Garrett M. Frampton  Siraj M. Ali  Alexa B. Schrock  Vincent A. Miller  Philip J. Stephens  Jeffrey S. Ross  Richard Frank
Affiliation:1. Pathology Department, Foundation Medicine Inc., Cambridge, Massachusetts, USA;2. Hematology and Oncology, Norwalk Hospital, Western Connecticut Health Network, Norwalk, Connecticut, USA;3. Radiology, Norwalk Hospital, Western Connecticut Health Network, Norwalk, Connecticut, USA;4. Clinical Genomics, Foundation Medicine, Inc., Cambridge, Massachusetts, USA;5. Clinical Development, Foundation Medicine, Inc., Cambridge, Massachusetts, USA;6. Department of Pathology and Laboratory Medicine, Albany Medical Center, Albany
Abstract:
Keywords:Palbociclib  Uterine leiomyosarcoma  CDKN2A  Comprehensive genomic profiling  Targeted therapy  Precision medicine
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号